| Document Date: 2013-12-23 10:31:23
Open Document File Size: 186,14 KBShare Result on Facebook
Company Alteon Inc. / / Currency pence / / Event FDA Phase / / MedicalCondition glioma cell line growth / Steven-Johnson syndrome / measurable residual disease / unresectable craniopharyngiomas / tumor / hypothalamic obesity / protocol specific disease / i.e. residual measurable disease / neurologic signs / tumors / disease / solid tumor AND / Craniopharyngiomas / recurrent craniopharyngiomas / isolated cyst / solid tumor / progressive disease / anaphylaxis / hepatitis C / toxic epidermal necrolysis / ELIGIBILITY CRITERIA Tumor / urticaria / angioedema / recurrent craniopharyngioma / hypersensitivity / resected tumor / newly diagnosed craniopharyngiomas / hypothalamic syndrome / cyst / depression / residual measurable disease / craniopharyngioma / progressive neurologic signs / brain tumors / bronchoconstriction / severe psychiatric illness / metastatic melanoma / / MedicalTreatment radiation therapy / radiosurgery / chemotherapy / surgery / Radiation / / Organization FDA / / Position RT / / Product phenytoin / PEGIntron / Peginterferon / PBTC-039 / / Technology alpha / radiation / chemotherapy / 2013 Protocol / 5 NCI Protocol / MRI / /
SocialTag |
NCI Protocol #: PBTC-039 Version Date: August 01, 2013 Protocol Abstract and Schema Phase II study of Peginterferon alfa-2b (PEGIntron) for pediatric patients with unresectable or recurrent craniopharyngioma.